Cargando…
SAT643 Patient Preference Questionnaire Response After Switching To Somapacitan After Taking Daily Gh: 2-year Results From REAL4
Disclosure: J. Blair: Advisory Board Member; Self; Novo Nordisk. Speaker; Self; Novo Nordisk, Ipsen. Other; Self; Novo Nordisk. B.S. Miller: Consulting Fee; Self; Abbvie, Bristol-Myers Squibb, Novo Nordisk, Pfizer, Inc., EMD Serono, Endo Pharmaceuticals. Grant Recipient; Self; Alexion Pharmaceutical...
Autores principales: | Blair, Joanne, Miller, Bradley Scott, Hojby, Michael, Maniatis, Aristides K, Mori, Jun, Boettcher, Volker, Kim, Ho-Seong, Bang, Rikke Beck, Fries Jensen, Lasse De, Polak, Michel, Horikawa, Reiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554129/ http://dx.doi.org/10.1210/jendso/bvad114.1082 |
Ejemplares similares
-
SAT642 Effective Gh Replacement With Once-weekly Somapacitan In Children With Gh Deficiency: 2-year Results From Real4
por: Miller, Bradley Scott, et al.
Publicado: (2023) -
Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH
por: Miller, Bradley S, et al.
Publicado: (2023) -
SAT437 Immunotherapy Induced Pituitary Apoplexy
por: Uddin, Ashraf, et al.
Publicado: (2023) -
Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial
por: Miller, Bradley S, et al.
Publicado: (2022) -
SAT438 Nivolumab Induced Endocrinopathies- Outcomes And Learning
por: Kethireddi, Keerthi Madhurya, et al.
Publicado: (2023)